Axonics Stock Cash And Equivalents

0I3 Stock  EUR 63.50  0.00  0.00%   
Axonics fundamentals help investors to digest information that contributes to Axonics' financial success or failures. It also enables traders to predict the movement of Axonics Stock. The fundamental analysis module provides a way to measure Axonics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Axonics stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Axonics Company Cash And Equivalents Analysis

Axonics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Cash

 = 

Bank Deposits

+

Liquidities

More About Cash And Equivalents | All Equity Analysis

Current Axonics Cash And Equivalents

    
  231.14 M  
Most of Axonics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Axonics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Competition

In accordance with the recently published financial statements, Axonics has 231.14 M in Cash And Equivalents. This is 71.84% lower than that of the Healthcare sector and 58.57% lower than that of the Medical Devices industry. The cash and equivalents for all Germany stocks is 91.45% higher than that of the company.

Axonics Cash And Equivalents Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Axonics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Axonics could also be used in its relative valuation, which is a method of valuing Axonics by comparing valuation metrics of similar companies.
Axonics is currently under evaluation in cash and equivalents category among its peers.

Axonics Fundamentals

About Axonics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Axonics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Axonics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Axonics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Other Information on Investing in Axonics Stock

Axonics financial ratios help investors to determine whether Axonics Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Axonics with respect to the benefits of owning Axonics security.